Evidence map›Paper›PMID 34605223›Full record

ArticleAdvanced healthcare materials2021

A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens.

Fernanda Langellotto, Maxence O Dellacherie, Chyenne Yeager, Hamza Ijaz, Jingyou Yu, Chi-An Cheng, Nikolaos Dimitrakakis, Benjamin T Seiler, Makda S Gebre, Tal Gilboa and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. T cells in SARS-CoV-2 infection and vaccination.Therapeutic advances in vaccines and immunotherapy · 2022
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Fernanda LangellottoWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Maxence O DellacherieWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Chyenne YeagerWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Hamza IjazWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Jingyou YuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
Chi-An ChengWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Nikolaos DimitrakakisWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Benjamin T SeilerWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Makda S GebreCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
Tal GilboaWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Rebecca JohnsonDepartment of Microbiology, Boston University School of Medicine and National Emerging Infectious Diseases Laboratories, Boston, MA, 02118, USA.
Nadia StormDepartment of Microbiology, Boston University School of Medicine and National Emerging Infectious Diseases Laboratories, Boston, MA, 02118, USA.
Sarai BardalesWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Amanda GravelineWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Des WhiteWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Christina M TringidesWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Mark J CartwrightWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Edward J DohertyWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Anna HonkoDepartment of Microbiology, Boston University School of Medicine and National Emerging Infectious Diseases Laboratories, Boston, MA, 02118, USA.
Anthony GriffithsDepartment of Microbiology, Boston University School of Medicine and National Emerging Infectious Diseases Laboratories, Boston, MA, 02118, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
David R WaltWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
David J MooneyWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.ORCID 0000-0001-6299-1194
Harvard University · USBoston University · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic demonstrates the importance of generating safe and efficacious vaccines that can be rapidly deployed against emerging pathogens. Subunit vaccines are considered among the safest, but proteins used in these typically lack strong immunogenicity, leading to poor immune responses. Here, a biomaterial COVID-19 vaccine based on a mesoporous silica rods (MSRs) platform is described. MSRs loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF), the toll-like receptor 4 (TLR-4) agonist monophosphoryl lipid A (MPLA), and SARS-CoV-2 viral protein antigens slowly release their cargo and form subcutaneous scaffolds that locally recruit and activate antigen-presenting cells (APCs) for the generation of adaptive immunity. MSR-based vaccines generate robust and durable cellular and humoral responses against SARS-CoV-2 antigens, including the poorly immunogenic receptor binding domain (RBD) of the spike (S) protein. Persistent antibodies over the course of 8 months are found in all vaccine configurations tested and robust in vitro viral neutralization is observed both in a prime-boost and a single-dose regimen. These vaccines can be fully formulated ahead of time or stored lyophilized and reconstituted with an antigen mixture moments before injection, which can facilitate its rapid deployment against emerging SARS-CoV-2 variants or new pathogens. Together, the data show a promising COVID-19 vaccine candidate and a generally adaptable vaccine platform against infectious pathogens.

Indexed as

COVID-19SARS-CoV-2Adaptive ImmunityAntibodies, ViralBiocompatible MaterialsCOVID-19 VaccinesHumansAntibodies, ViralBiocompatible MaterialsCOVID-19 VaccinesantibodiesCOVID-19cytotoxic T-cellsmesoporous silica rodsmonophosphoryl lipid A (MPLA)recombinant proteinsSARS-CoV-2vaccines

Identifiers

PMID34605223
PMCPMC8652677
OpenAlexW3204943360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.